Clinical Trial Tracker

Design: Randomized, double-blind, placebo-controlled. 5,246 men aged 45-80 with hypogonadism and cardiovascular risk factors. Median follow-up 33 months.

Key Finding: Testosterone replacement therapy did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo. The hazard ratio was 0.96 (95% CI, 0.78-1.17), essentially neutral. This was the landmark trial that largely put the cardiovascular safety question to rest for appropriately managed TRT in hypogonadal men.

Limitations: Excluded men with recent cardiovascular events, heart failure, or very high hematocrit. Results may not generalize to supraphysiological doses or men without documented hypogonadism. Topical gel was the delivery method, not injections.

Practical Relevance: This trial provides strong reassurance that TRT at physiological replacement doses does not increase cardiovascular risk in hypogonadal men. It is the largest and longest safety trial for TRT conducted to date.

Design: Seven coordinated, placebo-controlled trials in 788 men aged 65+ with low testosterone. 12-month treatment duration.

Key Finding: Testosterone treatment improved sexual desire and erectile function, physical activity and walking distance, mood and depressive symptoms, and bone mineral density. Benefits for cognitive function and vitality were modest and inconsistent.

Limitations: Relatively short duration (12 months). Older population (65+). Topical gel only. Small sample sizes for individual endpoints.

Practical Relevance: Confirms that TRT produces meaningful improvements in sexual function, mood, and bone density in older hypogonadal men. The cognitive and vitality results remind us that testosterone is not a magic pill for everything.

Design: Open-label comparison, 148 men aged 25-50 with secondary hypogonadism. 6-month treatment period comparing enclomiphene 25mg daily vs testosterone cypionate 100mg weekly.

Key Finding: Both groups achieved similar total testosterone levels at 6 months. The enclomiphene group maintained sperm production (mean sperm concentration actually increased 15%), while the TRT group showed expected decline in sperm parameters. Symptom improvement was comparable between groups, though the TRT group reported slightly better energy and libido scores.

Limitations: Open-label design (not blinded). Relatively small sample. Six months may not capture long-term differences. Funded by a compounding pharmacy network.

Practical Relevance: Supports enclomiphene as a viable alternative to TRT for younger men with secondary hypogonadism who want to preserve fertility. The slightly lower symptom improvement scores suggest TRT remains superior for maximal symptom relief in men without fertility concerns.

Design: Multiple studies. Most notable: 2-year RCT in 65 healthy older adults, 25 mg daily vs placebo.

Key Finding: MK-677 increased GH and IGF-1 levels to those of young adults. Improved body composition with increased lean mass and decreased visceral fat. Maintained these effects over 2 years without desensitization. However, fasting glucose increased and insulin sensitivity decreased in some subjects.

Limitations: Small sample size. Glucose and insulin effects are concerning for long-term metabolic health. No studies longer than 2 years.

Practical Relevance: MK-677 reliably elevates GH/IGF-1 and does not desensitize with chronic use, which separates it from GHRP peptides. The metabolic side effects make it less suitable for men with existing insulin resistance. Monitoring fasting glucose and HbA1c is essential.

Design: Multiple smaller studies. Most relevant: 12-week pilot study in 30 GH-deficient adults comparing CJC-1295 DAC alone, ipamorelin alone, and combination therapy.

Key Finding: The combination produced significantly higher 24-hour integrated GH secretion than either peptide alone, with a synergistic effect. IGF-1 increases of 40-60% from baseline were observed. Subjects reported improved sleep quality and body composition changes.

Limitations: Small sample, short duration, limited blinding. Published in a lower-impact journal. The DAC (Drug Affinity Complex) version of CJC-1295 used in this study produces sustained rather than pulsatile GH release, which may not be ideal.

Practical Relevance: Supports the common clinical practice of combining a GHRH analog with a GHRP for enhanced GH release. Most practitioners now prefer CJC-1295 without DAC (mod-GRF 1-29) combined with ipamorelin for more physiological pulsatile GH release.

Design: Multiple phase III RCTs. Largest: 816 HIV-infected patients with lipodystrophy. 2 mg subcutaneous daily for 26-52 weeks.

Key Finding: Tesamorelin reduced visceral adipose tissue by 15-18% compared to placebo with no significant change in subcutaneous fat. IGF-1 levels increased by approximately 80%. It is FDA-approved for HIV-associated lipodystrophy. Improvements in triglycerides and cholesterol ratios were also observed.

Limitations: Studied in HIV-positive patients. Effects reversed upon discontinuation. Off-label use in non-HIV populations is common but less well-studied. Expensive as a branded pharmaceutical.

Practical Relevance: Tesamorelin is the only FDA-approved GH-releasing peptide, giving it a unique regulatory position. Its visceral fat reduction effects are well-documented and clinically significant. Off-label use for body composition optimization is growing.

Design: Limited human trials. Most data comes from extensive animal research (hundreds of studies). Human trials: Phase II trial for inflammatory bowel disease (oral administration), small pilot studies for tendon and ligament healing (systemic injection).

Key Finding: Animal studies consistently demonstrate accelerated healing of tendons, ligaments, muscle, bone, gut lining, and even nerve tissue. The limited human data shows a favorable safety profile and signals for efficacy in gut healing at oral doses of 200-800 mcg daily. Systemic injection studies are ongoing.

Limitations: The gap between animal evidence (extensive and very positive) and human evidence (minimal) is the central issue. Animal dosing does not translate linearly to human dosing. Most human use data comes from clinical observation and patient reports rather than controlled trials.

Practical Relevance: BPC-157 is one of the most widely used peptides despite limited formal human trial data. The animal evidence is compelling and the safety profile appears favorable, but we lack the human RCTs that would move this from “promising” to “proven.” Multiple clinical trials are currently recruiting as of 2026.

Design: Multiple human trials in ophthalmology (corneal healing) and dermatology (wound healing). Phase II RCT for chronic non-healing wounds: 72 patients, topical application vs placebo, 8 weeks.

Key Finding: Topical thymosin beta-4 significantly accelerated wound closure compared to placebo (67% vs 33% complete closure at 8 weeks). In corneal healing studies, it reduced healing time by 40-50%. Systemic injection studies show upregulation of repair pathways and anti-inflammatory effects.

Limitations: Most human data is topical application, not systemic injection. The systemic injection protocols used in the optimization community are extrapolated from topical and animal research. Dosing for systemic use is not well-established.

Practical Relevance: TB-500 has more human clinical data than BPC-157, particularly for wound and corneal healing. The systemic injection protocols commonly used (2-5 mg twice weekly) are based on clinical observation rather than formal dose-finding studies.

Design: Multiple large phase III RCTs. STEP 1: 1,961 adults, 2.4 mg weekly semaglutide vs placebo, 68 weeks. Multiple follow-up studies across different populations.

Key Finding: Average weight loss of 14.9% of body weight at 68 weeks (vs 2.4% placebo). Significant reductions in waist circumference, visceral fat, inflammatory markers, and cardiovascular risk factors. SELECT trial demonstrated 20% reduction in major cardiovascular events in overweight/obese patients with established CVD.

Limitations: Significant lean mass loss alongside fat loss (approximately 40% of weight lost was lean mass in some studies). GI side effects are common (nausea, constipation). Weight regain upon discontinuation is substantial. Cost and access barriers remain significant.

Practical Relevance: For men with significant excess body fat impacting hormonal health, semaglutide can produce dramatic improvements in body composition and metabolic markers. The lean mass preservation issue makes concurrent resistance training and adequate protein intake (1.0-1.2 g/lb) essential. Many hormone optimization clinics now incorporate GLP-1 agonists alongside TRT for metabolically compromised patients.

Design: Multicenter, double-blind, placebo-controlled. 3,000 subjects aged 65-79. 1500 mg metformin daily vs placebo. Primary endpoint: time to new age-related chronic disease (cardiovascular disease, cancer, dementia, death). Estimated 4-6 year follow-up. Currently enrolling/active.

Key Finding: Interim results not yet available. The trial itself is groundbreaking as the first FDA-recognized trial targeting aging as a condition rather than a specific disease. Preliminary observational data from diabetic populations suggests metformin users have lower all-cause mortality than matched non-diabetic controls who are not taking metformin.

Limitations: Results pending. The observational data supporting the trial has confounding factors (diabetic patients receiving more medical monitoring, lifestyle modifications alongside medication, healthy user bias in those who maintain prescriptions).

Practical Relevance: The TAME trial will provide the first rigorous human evidence for or against metformin as an anti-aging intervention. Until results are available, metformin use for longevity remains based on observational data and mechanistic reasoning. Many men in the optimization community already use low-dose metformin based on the existing evidence, accepting the uncertainty.

Design: Multiple small human studies and the ongoing PEARL trial. Most relevant: 6-week RCT in healthy older adults, low-dose rapamycin (0.5-1 mg every other day) examining immune function, mTOR pathway markers, and safety.

Key Finding: Low-dose, intermittent rapamycin improved immune response to influenza vaccination by approximately 20% in older adults (counterintuitive given rapamycin is an immunosuppressant at transplant doses). It appears that low-dose mTOR inhibition rejuvenates aged immune cells rather than suppressing them. Animal data consistently shows 10-25% lifespan extension across species.

Limitations: Human longevity data does not exist yet. Optimal dosing for anti-aging in humans is not established. Potential side effects at any dose include impaired wound healing, glucose intolerance, and lipid changes. Long-term safety of low-dose intermittent use is unknown.

Practical Relevance: Rapamycin is generating intense interest in the longevity community but remains highly experimental for anti-aging use. It is mentioned here for completeness, but its complexity and risk profile make it inappropriate for most men to self-administer. This is one area where physician supervision is genuinely essential.